about
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks.Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments.Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based BiotherapeuticsPhysicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.Preferential interactions of trehalose, L-arginine.HCl and sodium chloride with therapeutically relevant IgG1 monoclonal antibodies.Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.Design and engineering of deimmunized biotherapeutics.Antibody drug conjugates.Biopharmaceutical Informatics: supporting biologic drug development via molecular modelling and informatics.Novel chemical degradation pathways of proteins mediated by tryptophan oxidation: tryptophan side chain fragmentation.Visual Detection of Denatured Glutathione Peptides: A Facile Method to Visibly Detect Heat Stressed Biomolecules.AlphaScreen-based homogeneous assay using a pair of 25-residue artificial proteins for high-throughput analysis of non-native IgG.Expression of PTEN-long mediated by CRISPR/Cas9 can repress U87 cell proliferation.Factors affecting the physical stability (aggregation) of peptide therapeutics.Multi-step conformational transitions in heat-treated protein therapeutics can be monitored in real time with temperature-controlled electrospray ionization mass spectrometry.Modulating the immune system through nanotechnology.Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.Monoclonal antibody higher order structure analysis by high throughput protein conformational array.Evidence for intermolecular domain exchange in the Fab domains of dimer and oligomers of an IgG1 monoclonal antibody.Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.
P2860
Q33442579-7E1F3D95-4844-4D7A-9D64-83D990B92D79Q33641909-C42B7892-D3CE-48C2-A9A9-1962181A5F79Q36095866-41C5016A-C857-4D5D-9D75-C71E95EEDA1CQ37703405-B809B102-0DED-4C24-90CC-F3B0244DD670Q38652096-8D30A4EC-CC56-44CD-9E3C-1925154FF7FCQ38781432-96EC4C54-7F03-4F83-A9D6-1AF677BEF009Q38870681-A2686E52-2017-4C5A-9766-81386B2FFBAAQ38873862-D7B2B9CA-DBB7-4733-A793-50F4F5498F1AQ38982236-E1B65839-3EDE-418B-87C1-A253CBA133C1Q39109386-72B8CB60-A396-49CC-9BE0-B31059766382Q41880923-0678C80C-5741-4801-8820-0758F6283F0AQ42367805-7DE801EC-153A-494A-8330-30DAA2691EC3Q45869005-EF00CC32-146D-4001-A6D0-F44644B6100EQ46259884-D2938F83-F1E5-48A4-86CC-269DB6C6745AQ47230430-F360C864-E5FA-4E03-A07D-7284AAD74BE9Q48630939-79780C73-67C3-45BE-9E05-F34B7F578BB8Q50034109-B5A161F7-969C-4F97-9B85-7BC2FB7A16C3Q50117760-5EDB381C-BD93-4FA4-B886-F5F6B3A390BDQ50127059-2B387F70-9A8E-4D2B-88EE-C6B8ED58C9DFQ50955425-643089AF-27ED-4BF0-A84E-9CA0BAF3D2EBQ52593621-821FFC0E-4581-4D51-B994-D024A8D8FF6E
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Immunogenicity of Therapeutic Protein Aggregates.
@en
type
label
Immunogenicity of Therapeutic Protein Aggregates.
@en
prefLabel
Immunogenicity of Therapeutic Protein Aggregates.
@en
P2093
P1476
Immunogenicity of Therapeutic Protein Aggregates.
@en
P2093
Balakrishnan S Moorthy
Ehab M Moussa
Elizabeth M Topp
Jainik P Panchal
Linda O Narhi
Marisa K Joubert
P304
P356
10.1016/J.XPHS.2015.11.002
P407
P577
2016-02-01T00:00:00Z